Key result
Ticagrelor achieved significantly lower platelet reactivity compared with prasugrel (45.2 vs 80.8 PRU; mean difference -35.6, 95% CI -55.2 to -15.9; P=0.001) in ACS patients with diabetes.
Why the study?
Does ticagrelor improve platelet inhibition compared to prasugrel in ACS patients with diabetes mellitus undergoing PCI?
Population
30 consecutive acute coronary syndrome patients with diabetes mellitus who had been pretreated with…
Comparison
Ticagrelor 90 mg twice daily for a 15-day… vs Prasugrel 10 mg once daily for a 15-day…
Design
RCT, Randomized in a crossover design, single-blind
Follow-up
15 days
Authors
Loading...
Supports ticagrelor preference for stronger platelet inhibition in diabetic ACS undergoing PCI; extends randomized PD data to this high-risk subgroup.
RCT (n=30)
Single-blind
Randomized crossover
No
Does ticagrelor improve platelet inhibition compared to prasugrel in ACS patients with diabetes mellitus undergoing PCI?
Mean Difference: -35.6 (95% CI -55.2–-15.9)
Absolute Event Rate: 45.2% vs 80.8%
p-value: p=0.001
Ticagrelor provides significantly greater platelet inhibition than prasugrel in diabetic patients with ACS undergoing PCI, though both agents effectively overcome high platelet reactivity.
Alexopoulos et al. (2013) conducted an RCT in Acute coronary syndrome with diabetes mellitus (n=30). Ticagrelor vs. Prasugrel 10 mg once daily was evaluated on Platelet reactivity (PR) measured in P2Y12 reaction units (PRU) (MD -35.6, 95% CI -55.2 to -15.9, p=0.001). Ticagrelor achieved significantly lower platelet reactivity compared with prasugrel (45.2 vs 80.8 PRU; mean difference -35.6, 95% CI -55.2 to -15.9; P=0.001) in ACS patients with diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: